Sutro Biopharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell STRO and other ETFs, options, and stocks.

About STRO

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. 

CEO
Jane Chung
CEOJane Chung
Employees
338
Employees338
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2003
Founded2003
Employees
338
Employees338

STRO Key Statistics

Market cap
75.57M
Market cap75.57M
Price-Earnings ratio
-0.35
Price-Earnings ratio-0.35
Dividend yield
Dividend yield
Average volume
121.33K
Average volume121.33K
High today
$9.25
High today$9.25
Low today
$8.66
Low today$8.66
Open price
$9.01
Open price$9.01
Volume
46.46K
Volume46.46K
52 Week high
$21.50
52 Week high$21.50
52 Week low
$5.23
52 Week low$5.23

Stock Snapshot

Sutro Biopharma(STRO) stock is priced at $8.87, giving the company a market capitalization of 75.57M. It carries a P/E multiple of -0.35.

During the trading session on 2025-12-18, Sutro Biopharma(STRO) shares reached a daily high of $9.25 and a low of $8.66. At a current price of $8.87, the stock is +2.4% higher than the low and still -4.1% under the high.

Trading volume for Sutro Biopharma(STRO) stock has reached 46.46K, versus its average volume of 121.33K.

The stock's 52-week range extends from a low of $5.23 to a high of $21.50.

The stock's 52-week range extends from a low of $5.23 to a high of $21.50.

STRO News

TipRanks 23h
Sutro Biopharma Regains Nasdaq Listing Compliance

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...

TipRanks 23h
Sutro Biopharma regains compliance with Nasdaq

Sutro Biopharma (STRO) announced it has regained compliance with Nasdaq continued listing standard for minimum share price under Rule 5450 of the Nasdaq Listing...

TipRanks 4d
Sutro Biopharma’s Promising Phase 1 Study on STRO-004: A Potential Game-Changer in Cancer Treatment

Sutro Biopharma (STRO) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level...

Analyst ratings

50%

of 10 ratings
Buy
50%
Hold
40%
Sell
10%

People also own

Based on the portfolios of people who own STRO. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.